Dr. Sándor Nardai Leads Algernon Phase 2a DMT Stroke Study
Algernon Pharmaceuticals’ subsidiary, Algernon NeuroScience, has appointed Dr. Sándor Nardai as the Principal Investigator for its Phase 2a DMT...
Jon Napitupulu
Third Harmonic Bio Announces Phase 1 THB335 Clinical Results & Update
Third Harmonic Bio announced positive Phase 1 results for THB335, an oral KIT inhibitor, paving the way for a...
Padcev® Plus Keytruda® Shows Long-Term Efficacy in Urothelial Cancer
Pfizer and Astellas announced updated results from the Phase 3 EV-302 trial, showing sustained overall survival (OS) and progression-free...
Achieve Life Sciences Positive Orca-OL Trial Results
Achieve Life Sciences announced positive safety results from the second review of their ongoing ORCA-OL trial for cytisinicline, a...
Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025
Ashvattha Therapeutics announced positive Phase 2 trial data for its subcutaneously administered nanomedicine, Migaldendranib (MGB), designed to treat retinal...
Rad 101 Detects Brain Metastases in New Clinical Trial
Radiopharm Theranostics announced positive results from a study using a novel imaging approach with RAD 101 (18F-Pivalate) to detect...
eGenesis Announces Success: Second Patient Receives Genetically Engineered Porcine Kidney
eGenesis successfully transplanted a genetically modified pig kidney into a second patient with end-stage kidney disease. The procedure, part...
Cyclo Therapeutics’ Positive Phase 3 Open-Label Sub-Study Data in Young Patients
Cyclo Therapeutics presented data from its pivotal Phase 3 TransportNPC™ trial of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1...
Ampligen® & Flumist®: AIM Immunotech’s Innovative Avian Flu Trial
AIM ImmunoTech Inc. is initiating a plan to further develop Ampligen as a vaccine adjuvant for avian influenza. The...
Eylea HD: 3-Year Results Show Durable Vision Gains in Wet AMD
Regeneron announced positive three-year results from an extension study of the Phase 3 PULSAR trial for EYLEA HD (aflibercept...